Released Sep 14, 2026, after the close
10-Q filed Sep 14, 2026, 45 days after period end · 0001654954-26-008346
What the release said
On September 14, 2026, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the quarter ended July 31, 2026.
Revenue for the three and nine months ended July 31, 2026 was approximately $2.3 million and $7.3 million, respectively, representing increases of approximately $0.4 million and $0.5 million compared to the same periods last year.¶2
For the three and nine months ended July 31, 2026, the Company reported a net loss of $14 thousand and net income of approximately $252 thousand, respectively, representing improvements of approximately $190 thousand and $352 thousand compared with the corresponding periods of the prior year.¶3
- Revenue
- $2.3 million approximately, for the three months ended July 31, 2026¶2
- Revenue
- $7.3 million approximately, for the nine months ended July 31, 2026¶2
- Net loss
- $14 thousand for the three months ended July 31, 2026¶3
- Net income
- $252 thousand approximately, for the nine months ended July 31, 2026¶3
- Revenue increase
- $0.4 million approximately, for the three months ended July 31, 2026 compared to the same period last year¶2
- Revenue increase
- $0.5 million approximately, for the nine months ended July 31, 2026 compared to the same period last year¶2
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $2.34M | $1.96M | $2.42M | $4.58M |
| Net Income | -$14.22K | -$204.25K | -$309.19K | $526.24K |
| EPS Diluted | -$0.00 | -$0.01 | $0.01 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR